Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 877 to 888 of 893 entries
Sorted by: Best Match Show Resources per page
Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.

United European gastroenterology journal

Mader O, Juillerat P, Biedermann L, Michetti P, Hruz P, Pittet V, Rogler G, Zahnd-Straumann N, Seibold F.
PMID: 33203339
United European Gastroenterol J. 2021 Apr;9(3):398-406. doi: 10.1177/2050640620965106. Epub 2021 Feb 26.

BACKGROUND: Vedolizumab (VDZ), a humanised monoclonal antibody against a4ß7-integrin, has shown efficacy in inflammatory bowel disease (IBD). It is of importance to assess the mid-to long-term efficacy of VDZ using real-life data.OBJECTIVE: Our study aimed to determine the efficacy...

Cite
Mader O, Juillerat P, Biedermann L, et al. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements. United European Gastroenterol J. 2021;9(3):398-406doi: 10.1177/2050640620965106.
Mader, O., Juillerat, P., Biedermann, L., Michetti, P., Hruz, P., Pittet, V., Rogler, G., Zahnd-Straumann, N., & Seibold, F. (2021). Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements. United European gastroenterology journal, 9(3), 398-406. https://doi.org/10.1177/2050640620965106
Mader, Orla, et al. "Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements." United European gastroenterology journal vol. 9,3 (2021): 398-406. doi: https://doi.org/10.1177/2050640620965106
Mader O, Juillerat P, Biedermann L, Michetti P, Hruz P, Pittet V, Rogler G, Zahnd-Straumann N, Seibold F. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements. United European Gastroenterol J. 2021 Apr;9(3):398-406. doi: 10.1177/2050640620965106. Epub 2021 Feb 26. PMID: 33203339; PMCID: PMC8259282.
Copy Download .nbib Format: NLM
Prevalence of hepatitis D virus co-infection in Austria - Finding the needle in the haystack.

United European gastroenterology journal

Sonneveld MJ, Maasoumy B.
PMID: 34817935
United European Gastroenterol J. 2021 Dec;9(10):1105-1106. doi: 10.1002/ueg2.12177. Epub 2021 Nov 24.

No abstract available.

Cite
Sonneveld MJ, Maasoumy B. Prevalence of hepatitis D virus co-infection in Austria - Finding the needle in the haystack. United European Gastroenterol J. 2021;9(10):1105-1106doi: 10.1002/ueg2.12177.
Sonneveld, M. J., & Maasoumy, B. (2021). Prevalence of hepatitis D virus co-infection in Austria - Finding the needle in the haystack. United European gastroenterology journal, 9(10), 1105-1106. https://doi.org/10.1002/ueg2.12177
Sonneveld, Milan J, and Maasoumy, Benjamin. "Prevalence of hepatitis D virus co-infection in Austria - Finding the needle in the haystack." United European gastroenterology journal vol. 9,10 (2021): 1105-1106. doi: https://doi.org/10.1002/ueg2.12177
Sonneveld MJ, Maasoumy B. Prevalence of hepatitis D virus co-infection in Austria - Finding the needle in the haystack. United European Gastroenterol J. 2021 Dec;9(10):1105-1106. doi: 10.1002/ueg2.12177. Epub 2021 Nov 24. PMID: 34817935; PMCID: PMC8672078.
Copy Download .nbib Format: NLM
Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

United European gastroenterology journal

Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Fehrenbach U, Auer TA, Gebauer B, Kloeckner R.
PMID: 34918471
United European Gastroenterol J. 2021 Dec 16; doi: 10.1002/ueg2.12188. Epub 2021 Dec 16.

BACKGROUND: Clinically evident portal hypertension (CEPH) was previously identified as a prognostic factor for patients with hepatocellular carcinoma (HCC). However, little is known about the prognostic influence of CEPH on the long-term outcome of patients with HCC undergoing transarterial...

Cite
Müller L, Hahn F, Mähringer-Kunz A, et al. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United European Gastroenterol J. 2021;doi: 10.1002/ueg2.12188.
Müller, L., Hahn, F., Mähringer-Kunz, A., Stoehr, F., Gairing, S. J., Foerster, F., Weinmann, A., Galle, P. R., Mittler, J., Pinto Dos Santos, D., Pitton, M. B., Düber, C., Fehrenbach, U., Auer, T. A., Gebauer, B., & Kloeckner, R. (2021). Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United European gastroenterology journal, . https://doi.org/10.1002/ueg2.12188
Müller, Lukas, et al. "Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization." United European gastroenterology journal vol. (2021). doi: https://doi.org/10.1002/ueg2.12188
Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Fehrenbach U, Auer TA, Gebauer B, Kloeckner R. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United European Gastroenterol J. 2021 Dec 16; doi: 10.1002/ueg2.12188. Epub 2021 Dec 16. PMID: 34918471.
Copy Download .nbib Format: NLM
Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population.

United European gastroenterology journal

Tornkvist NT, Aziz I, Whitehead WE, Sperber AD, Palsson OS, Hreinsson JP, Simrén M, Törnblom H.
PMID: 34599559
United European Gastroenterol J. 2021 Dec;9(10):1178-1188. doi: 10.1002/ueg2.12153. Epub 2021 Oct 01.

BACKGROUND: Irritable bowel syndrome (IBS) is highly prevalent worldwide but mechanisms for healthcare seeking behaviours in this patient group are poorly understood.OBJECTIVE: To describe healthcare utilization and identify factors associated with seeking healthcare amongst IBS subjects in the general...

Cite
Tornkvist NT, Aziz I, Whitehead WE, et al. Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. United European Gastroenterol J. 2021;9(10):1178-1188doi: 10.1002/ueg2.12153.
Tornkvist, N. T., Aziz, I., Whitehead, W. E., Sperber, A. D., Palsson, O. S., Hreinsson, J. P., Simrén, M., & Törnblom, H. (2021). Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. United European gastroenterology journal, 9(10), 1178-1188. https://doi.org/10.1002/ueg2.12153
Tornkvist, Navkiran T, et al. "Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population." United European gastroenterology journal vol. 9,10 (2021): 1178-1188. doi: https://doi.org/10.1002/ueg2.12153
Tornkvist NT, Aziz I, Whitehead WE, Sperber AD, Palsson OS, Hreinsson JP, Simrén M, Törnblom H. Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. United European Gastroenterol J. 2021 Dec;9(10):1178-1188. doi: 10.1002/ueg2.12153. Epub 2021 Oct 01. PMID: 34599559; PMCID: PMC8672084.
Copy Download .nbib Format: NLM
Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation.

United European gastroenterology journal

Allocca M, Filippi E, Costantino A, Bonovas S, Fiorino G, Furfaro F, Peyrin-Biroulet L, Fraquelli M, Caprioli F, Danese S.
PMID: 33349199
United European Gastroenterol J. 2021 May;9(4):438-442. doi: 10.1177/2050640620980203. Epub 2021 Feb 16.

INTRODUCTION: The aim of this study was to provide an external validation of bowel ultrasound (US) predictors of activity in ulcerative colitis (UC) and quantitative Milan Ultrasound Criteria (MUC).METHODS: Forty-three consecutive patients with UC (16 in endoscopic remission and...

Cite
Allocca M, Filippi E, Costantino A, et al. Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. United European Gastroenterol J. 2021;9(4):438-442doi: 10.1177/2050640620980203.
Allocca, M., Filippi, E., Costantino, A., Bonovas, S., Fiorino, G., Furfaro, F., Peyrin-Biroulet, L., Fraquelli, M., Caprioli, F., & Danese, S. (2021). Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. United European gastroenterology journal, 9(4), 438-442. https://doi.org/10.1177/2050640620980203
Allocca, Mariangela, et al. "Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation." United European gastroenterology journal vol. 9,4 (2021): 438-442. doi: https://doi.org/10.1177/2050640620980203
Allocca M, Filippi E, Costantino A, Bonovas S, Fiorino G, Furfaro F, Peyrin-Biroulet L, Fraquelli M, Caprioli F, Danese S. Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. United European Gastroenterol J. 2021 May;9(4):438-442. doi: 10.1177/2050640620980203. Epub 2021 Feb 16. PMID: 33349199; PMCID: PMC8259285.
Copy Download .nbib Format: NLM
Current status and limitations of artificial intelligence in colonoscopy.

United European gastroenterology journal

Hann A, Troya J, Fitting D.
PMID: 34617420
United European Gastroenterol J. 2021 Jun;9(5):527-533. doi: 10.1002/ueg2.12108. Epub 2021 Jun 07.

BACKGROUND: Artificial intelligence (AI) using deep learning methods for polyp detection (CADe) and characterization (CADx) is on the verge of clinical application. CADe already implied its potential use in randomized controlled trials. Further efforts are needed to take CADx...

Cite
Hann A, Troya J, Fitting D. Current status and limitations of artificial intelligence in colonoscopy. United European Gastroenterol J. 2021;9(5):527-533doi: 10.1002/ueg2.12108.
Hann, A., Troya, J., & Fitting, D. (2021). Current status and limitations of artificial intelligence in colonoscopy. United European gastroenterology journal, 9(5), 527-533. https://doi.org/10.1002/ueg2.12108
Hann, Alexander, et al. "Current status and limitations of artificial intelligence in colonoscopy." United European gastroenterology journal vol. 9,5 (2021): 527-533. doi: https://doi.org/10.1002/ueg2.12108
Hann A, Troya J, Fitting D. Current status and limitations of artificial intelligence in colonoscopy. United European Gastroenterol J. 2021 Jun;9(5):527-533. doi: 10.1002/ueg2.12108. Epub 2021 Jun 07. PMID: 34617420; PMCID: PMC8259277.
Copy Download .nbib Format: NLM
The effectiveness of rotating versus single course antibiotics for small intestinal bacterial overgrowth.

United European gastroenterology journal

Richard N, Desprez C, Wuestenberghs F, Leroi AM, Gourcerol G, Melchior C.
PMID: 34241973
United European Gastroenterol J. 2021 Jul;9(6):645-654. doi: 10.1002/ueg2.12116. Epub 2021 Jul 09.

BACKGROUND: Small intestinal bacterial overgrowth treatment is usually based on antibiotics with no guidelines available.OBJECTIVE: This study aimed to investigate the efficacy of different antibiotics to treat small intestinal bacterial overgrowth.METHODS: Consecutive patients referred to our tertiary center and...

Cite
Richard N, Desprez C, Wuestenberghs F, et al. The effectiveness of rotating versus single course antibiotics for small intestinal bacterial overgrowth. United European Gastroenterol J. 2021;9(6):645-654doi: 10.1002/ueg2.12116.
Richard, N., Desprez, C., Wuestenberghs, F., Leroi, A. M., Gourcerol, G., & Melchior, C. (2021). The effectiveness of rotating versus single course antibiotics for small intestinal bacterial overgrowth. United European gastroenterology journal, 9(6), 645-654. https://doi.org/10.1002/ueg2.12116
Richard, Nicolas, et al. "The effectiveness of rotating versus single course antibiotics for small intestinal bacterial overgrowth." United European gastroenterology journal vol. 9,6 (2021): 645-654. doi: https://doi.org/10.1002/ueg2.12116
Richard N, Desprez C, Wuestenberghs F, Leroi AM, Gourcerol G, Melchior C. The effectiveness of rotating versus single course antibiotics for small intestinal bacterial overgrowth. United European Gastroenterol J. 2021 Jul;9(6):645-654. doi: 10.1002/ueg2.12116. Epub 2021 Jul 09. PMID: 34241973; PMCID: PMC8280793.
Copy Download .nbib Format: NLM
Stools' donor recruitment, a challenge in pandemic times.

United European gastroenterology journal

Estevinho MM.
PMID: 34687164
United European Gastroenterol J. 2021 Nov;9(9):993-994. doi: 10.1002/ueg2.12168. Epub 2021 Oct 22.

No abstract available.

Cite
Estevinho MM. Stools' donor recruitment, a challenge in pandemic times. United European Gastroenterol J. 2021;9(9):993-994doi: 10.1002/ueg2.12168.
Estevinho, M. M. (2021). Stools' donor recruitment, a challenge in pandemic times. United European gastroenterology journal, 9(9), 993-994. https://doi.org/10.1002/ueg2.12168
Estevinho, Maria Manuela. "Stools' donor recruitment, a challenge in pandemic times." United European gastroenterology journal vol. 9,9 (2021): 993-994. doi: https://doi.org/10.1002/ueg2.12168
Estevinho MM. Stools' donor recruitment, a challenge in pandemic times. United European Gastroenterol J. 2021 Nov;9(9):993-994. doi: 10.1002/ueg2.12168. Epub 2021 Oct 22. PMID: 34687164; PMCID: PMC8598955.
Copy Download .nbib Format: NLM
Thanks to Partners, Sponsor and Exhibitors.

United European gastroenterology journal

[No authors listed]
PMID: 33520232
United European Gastroenterol J. 2017 Oct;5(5):v-vi. doi: 10.1177/2050640617725666. Epub 2017 Oct 29.

No abstract available.

Cite
Thanks to Partners, Sponsor and Exhibitors. United European Gastroenterol J. 2017;5(5):v-vidoi: 10.1177/2050640617725666.
(2017). Thanks to Partners, Sponsor and Exhibitors. United European gastroenterology journal, 5(5), v-vi. https://doi.org/10.1177/2050640617725666
"Thanks to Partners, Sponsor and Exhibitors." United European gastroenterology journal vol. 5,5 (2017): v-vi. doi: https://doi.org/10.1177/2050640617725666
Thanks to Partners, Sponsor and Exhibitors. United European Gastroenterol J. 2017 Oct;5(5):v-vi. doi: 10.1177/2050640617725666. Epub 2017 Oct 29. PMID: 33520232; PMCID: PMC7672680.
Copy Download .nbib Format: NLM
The gastrointestinal tract in hunger and satiety signalling.

United European gastroenterology journal

Tack J, Verbeure W, Mori H, Schol J, Van den Houte K, Huang IH, Balsiger L, Broeders B, Colomier E, Scarpellini E, Carbone F.
PMID: 34153172
United European Gastroenterol J. 2021 Jul;9(6):727-734. doi: 10.1002/ueg2.12097. Epub 2021 Jun 21.

BACKGROUND: Different peripheral pathways are implicated in the regulation of the food ingestion-digestion cycle.METHODS: Narrative review on gastrointestinal mechanisms involved in satiety and hunger signalling.RESULTS: Combined mechano- and chemoreceptors, peripherally released peptide hormones and neural pathways provide feedback to...

Cite
Tack J, Verbeure W, Mori H, et al. The gastrointestinal tract in hunger and satiety signalling. United European Gastroenterol J. 2021;9(6):727-734doi: 10.1002/ueg2.12097.
Tack, J., Verbeure, W., Mori, H., Schol, J., Van den Houte, K., Huang, I. H., Balsiger, L., Broeders, B., Colomier, E., Scarpellini, E., & Carbone, F. (2021). The gastrointestinal tract in hunger and satiety signalling. United European gastroenterology journal, 9(6), 727-734. https://doi.org/10.1002/ueg2.12097
Tack, Jan, et al. "The gastrointestinal tract in hunger and satiety signalling." United European gastroenterology journal vol. 9,6 (2021): 727-734. doi: https://doi.org/10.1002/ueg2.12097
Tack J, Verbeure W, Mori H, Schol J, Van den Houte K, Huang IH, Balsiger L, Broeders B, Colomier E, Scarpellini E, Carbone F. The gastrointestinal tract in hunger and satiety signalling. United European Gastroenterol J. 2021 Jul;9(6):727-734. doi: 10.1002/ueg2.12097. Epub 2021 Jun 21. PMID: 34153172; PMCID: PMC8280794.
Copy Download .nbib Format: NLM
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study.

United European gastroenterology journal

Goessens L, Colombel JF, Outtier A, Ferrante M, Sabino J, Judge C, Saeidi R, Rabbitt L, Armuzzi A, Domenech E, Michalopoulos G, Cremer A, García-Alonso FJ, Molnar T, Karmiris K, Gecse K, Van Oostrom J, Löwenberg M, Farkas K, Atreya R, Ribaldone DG, Selinger C, Hoentjen F, Bihin B, Sebastian S, Rahier JF.
PMID: 34694746
United European Gastroenterol J. 2021 Dec;9(10):1136-1147. doi: 10.1002/ueg2.12170. Epub 2021 Oct 25.

BACKGROUND AND AIMS: Few data are available regarding the combination of biologics or small molecules in inflammatory bowel disease (IBD) patients. We report safety and efficacy of such combinations through a retrospective multicentre series.METHODS: Combination therapy was defined as...

Cite
Goessens L, Colombel JF, Outtier A, et al. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. United European Gastroenterol J. 2021;9(10):1136-1147doi: 10.1002/ueg2.12170.
Goessens, L., Colombel, J. F., Outtier, A., Ferrante, M., Sabino, J., Judge, C., Saeidi, R., Rabbitt, L., Armuzzi, A., Domenech, E., Michalopoulos, G., Cremer, A., García-Alonso, F. J., Molnar, T., Karmiris, K., Gecse, K., Van Oostrom, J., Löwenberg, M., Farkas, K., Atreya, R., Ribaldone, D. G., Selinger, C., Hoentjen, F., Bihin, B., Sebastian, S., & Rahier, J. F. (2021). Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. United European gastroenterology journal, 9(10), 1136-1147. https://doi.org/10.1002/ueg2.12170
Goessens, Laurent, et al. "Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study." United European gastroenterology journal vol. 9,10 (2021): 1136-1147. doi: https://doi.org/10.1002/ueg2.12170
Goessens L, Colombel JF, Outtier A, Ferrante M, Sabino J, Judge C, Saeidi R, Rabbitt L, Armuzzi A, Domenech E, Michalopoulos G, Cremer A, García-Alonso FJ, Molnar T, Karmiris K, Gecse K, Van Oostrom J, Löwenberg M, Farkas K, Atreya R, Ribaldone DG, Selinger C, Hoentjen F, Bihin B, Sebastian S, Rahier JF. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. United European Gastroenterol J. 2021 Dec;9(10):1136-1147. doi: 10.1002/ueg2.12170. Epub 2021 Oct 25. PMID: 34694746.
Copy Download .nbib Format: NLM
If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs.

United European gastroenterology journal

Von den Hoff DW, Berden FAC, Schellekens AFA.
PMID: 34687156
United European Gastroenterol J. 2021 Dec;9(10):1101-1102. doi: 10.1002/ueg2.12167. Epub 2021 Oct 22.

No abstract available.

Cite
Von den Hoff DW, Berden FAC, Schellekens AFA. If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs. United European Gastroenterol J. 2021;9(10):1101-1102doi: 10.1002/ueg2.12167.
Von den Hoff, D. W., Berden, F. A. C., & Schellekens, A. F. A. (2021). If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs. United European gastroenterology journal, 9(10), 1101-1102. https://doi.org/10.1002/ueg2.12167
Von den Hoff, Daan W, et al. "If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs." United European gastroenterology journal vol. 9,10 (2021): 1101-1102. doi: https://doi.org/10.1002/ueg2.12167
Von den Hoff DW, Berden FAC, Schellekens AFA. If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs. United European Gastroenterol J. 2021 Dec;9(10):1101-1102. doi: 10.1002/ueg2.12167. Epub 2021 Oct 22. PMID: 34687156.
Copy Download .nbib Format: NLM
Showing 877 to 888 of 893 entries